iX Biopharma Ltd. (SGX:42C)

iX Biopharma Revenue

In the fiscal year ending June 30, 2026, iX Biopharma had annual revenue of 6.85M SGD, down -11.77%. iX Biopharma had revenue of 2.09M in the quarter ending June 30, 2026, a decrease of -6.62%. That makes iX Biopharma the 39,730th largest company in the world by revenue and 479th in Singapore.

• Revenue: 6.85M
• Revenue Growth: -11.77%
• P/S Ratio: 74.19
• Revenue / Employee: 185.22K
• Employees: 37
• Market Cap: 546.66M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Specialty Pharmaceuticals 5.63M 76.9%
• Nutraceutical 1.69M 23.1%

By Geography

Chart

• Australia 3.78M 55.2%
• United States of America 1.98M 28.9%
• China 675.00K 9.8%
• Singapore and Others 416.00K 6.1%

Fiscal year ended Jun 30, 2026 See the full iX Biopharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	6.85M	-914.00K	-11.77%
Jun 30, 2025	7.77M	1.81M	30.34%
Jun 30, 2024	5.96M	46.00K	0.78%
Jun 30, 2023	5.91M	-8.48M	-58.91%
Jun 30, 2022	14.39M	12.65M	724.64%

Data Source: S&P Global Market Intelligence Last updated: Sep 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 26, 2026

Data Sources Report a data error